| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 04/01/2025 | 00:57 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:VTYX | Ventyx Biosciences Inc |
| 27/12/2024 | 22:46 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:VTYX | Ventyx Biosciences Inc |
| 18/11/2024 | 06:15 | Edgar (US Regulatory) | Form EFFECT - Notice of Effectiveness | NASDAQ:VTYX | Ventyx Biosciences Inc |
| 15/11/2024 | 22:59 | Edgar (US Regulatory) | Form 424B3 - Prospectus [Rule 424(b)(3)] | NASDAQ:VTYX | Ventyx Biosciences Inc |
| 07/11/2024 | 23:13 | Edgar (US Regulatory) | Form S-3 - Registration statement under Securities Act of 1933 | NASDAQ:VTYX | Ventyx Biosciences Inc |
| 07/11/2024 | 22:58 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:VTYX | Ventyx Biosciences Inc |
| 07/11/2024 | 22:10 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:VTYX | Ventyx Biosciences Inc |
| 07/11/2024 | 22:05 | GlobeNewswire Inc. | Ventyx Biosciences Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Progress | NASDAQ:VTYX | Ventyx Biosciences Inc |
| 15/10/2024 | 14:00 | GlobeNewswire Inc. | Ventyx Biosciences Presents New 52-Week Results from the Phase 2 Trial of VTX002 (Tamuzimod) in Ulcerative Colitis at UEG Week 2024 | NASDAQ:VTYX | Ventyx Biosciences Inc |
| 30/09/2024 | 22:40 | Edgar (US Regulatory) | Form D - Notice of Exempt Offering of Securities | NASDAQ:VTYX | Ventyx Biosciences Inc |
| 23/09/2024 | 14:00 | GlobeNewswire Inc. | Ventyx Biosciences Announces $27 Million Strategic Investment from Sanofi | NASDAQ:VTYX | Ventyx Biosciences Inc |
| 09/09/2024 | 22:47 | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of securities | NASDAQ:VTYX | Ventyx Biosciences Inc |
| 06/09/2024 | 14:00 | GlobeNewswire Inc. | Ventyx Biosciences Announces Initiation of Dosing in a Phase 2a Trial of VTX3232 in Patients with Early Parkinson’s Disease | NASDAQ:VTYX | Ventyx Biosciences Inc |
| 30/08/2024 | 14:00 | GlobeNewswire Inc. | Ventyx Biosciences Announces Departure of Chief Financial Officer | NASDAQ:VTYX | Ventyx Biosciences Inc |
| 28/08/2024 | 14:00 | GlobeNewswire Inc. | Ventyx Biosciences to Participate in Two Upcoming Investor Conferences | NASDAQ:VTYX | Ventyx Biosciences Inc |
| 08/08/2024 | 22:01 | GlobeNewswire Inc. | Ventyx Biosciences Reports Second Quarter 2024 Financial Results and Highlights Recent Corporate Progress | NASDAQ:VTYX | Ventyx Biosciences Inc |
| 29/07/2024 | 14:00 | GlobeNewswire Inc. | Ventyx Biosciences Announces Results from the Phase 2 Trial of VTX958 in Participants with Moderately to Severely Active Crohn’s Disease | NASDAQ:VTYX | Ventyx Biosciences Inc |
| 05/06/2024 | 22:01 | GlobeNewswire Inc. | Ventyx Biosciences Announces Positive Preclinical Data for CNS-Penetrant NLRP3 Inhibitor VTX3232 Demonstrating Reversal of Obesity and Improvements in Cardiometabolic and Inflammatory Markers | NASDAQ:VTYX | Ventyx Biosciences Inc |
| 16/05/2024 | 22:05 | GlobeNewswire Inc. | Ventyx Biosciences to Participate in Three Upcoming Investor Conferences | NASDAQ:VTYX | Ventyx Biosciences Inc |
| 16/05/2024 | 14:00 | GlobeNewswire Inc. | Ventyx Biosciences Announces Appointment of Matthew Moore as Chief Operating Officer | NASDAQ:VTYX | Ventyx Biosciences Inc |
| 09/05/2024 | 22:01 | GlobeNewswire Inc. | Ventyx Biosciences Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Progress | NASDAQ:VTYX | Ventyx Biosciences Inc |
| 02/05/2024 | 22:05 | GlobeNewswire Inc. | Ventyx Biosciences to Report First Quarter 2024 Financial Results on May 9, 2024 | NASDAQ:VTYX | Ventyx Biosciences Inc |
| 26/04/2024 | 11:45 | PR Newswire (US) | The Gross Law Firm Reminds Ventyx Biosciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 30, 2024 - VTYX | NASDAQ:VTYX | Ventyx Biosciences Inc |
| 19/04/2024 | 12:00 | PR Newswire (US) | Ventyx Biosciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before April 30, 2024 to Discuss Your Rights - VTYX | NASDAQ:VTYX | Ventyx Biosciences Inc |
| 16/04/2024 | 11:45 | PR Newswire (US) | The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 30, 2024 in Ventyx Biosciences, Inc. Lawsuit - VTYX | NASDAQ:VTYX | Ventyx Biosciences Inc |
| 09/04/2024 | 12:10 | PR Newswire (US) | Investors in Ventyx Biosciences, Inc. Should Contact The Gross Law Firm Before April 30, 2024 to Discuss Your Rights - VTYX | NASDAQ:VTYX | Ventyx Biosciences Inc |
| 05/04/2024 | 11:45 | PR Newswire (US) | Investors who lost money on Ventyx Biosciences, Inc.(VTYX) should contact The Gross Law Firm about pending Class Action - VTYX | NASDAQ:VTYX | Ventyx Biosciences Inc |
| 26/03/2024 | 10:45 | PR Newswire (US) | Ventyx Biosciences, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - VTYX | NASDAQ:VTYX | Ventyx Biosciences Inc |
| 11/03/2024 | 12:00 | GlobeNewswire Inc. | Ventyx Biosciences Reports Clinical Data for its NLRP3 Inhibitor Portfolio and Provides Pipeline Updates at Virtual Investor Event | NASDAQ:VTYX | Ventyx Biosciences Inc |
| 08/03/2024 | 22:05 | Edgar (US Regulatory) | Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] | NASDAQ:VTYX | Ventyx Biosciences Inc |